Abbott reports first-quarter results; increases outlook for underlying base business

Sample article from our Health Care Sector

ABBOTT PARK, Illinois , April 20, 2023 (press release) –

  • Sales of $9.7 billion driven by strong underlying base business performance
  • Reported sales decreased 18.1 percent due to anticipated decline in COVID-19 testing-related sales versus prior year
  • Organic sales growth for underlying base business of 10.0 percent, led by Medical Devices, Established Pharmaceuticals and Nutrition

Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2023.

  • First-quarter GAAP diluted EPS of $0.75 and adjusted diluted EPS of $1.03, which excludes specified items.
  • Projected full-year 2023 diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25 remains unchanged.
  • Projected full-year adjusted EPS from continuing operations of $4.30 to $4.50 remains unchanged and now reflects an increased outlook for the underlying base business offset by a lower forecasted earnings contribution from COVID-19 testing-related sales.
  • Abbott now projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales1, of at least high single-digitsand COVID-19 testing-related sales of approximately $1.5 billion.
  • In January, Abbott announced U.S. Food and Drug Administration (FDA) approval of Navitor®, its second-generation transcatheter aortic valve implantation system, for people with severe aortic stenosis who are at high risk for surgery.
  • In March, data was presented at the American College of Cardiology Scientific Sessions showing Abbott's TriClip® system was superior to current medical therapy in treating patients with severe tricuspid regurgitation, or a leaky tricuspid heart valve.
  • In March, Abbott's market-leading FreeStyle Libre® continuous glucose monitoring system received U.S. FDA clearance for integration with automated insulin delivery systems. Abbott is partnering with leading insulin pump manufacturers to integrate their systems with FreeStyle Libre 2 and FreeStyle Libre 3 as soon as possible.

"Our first-quarter results reflect a very strong start to the year," said Robert B. Ford, chairman and chief executive officer, Abbott. "Growth in our underlying base businesses accelerated, including particularly strong results in Medical Devices, Established Pharmaceuticals and Nutrition."

FIRST-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange, as well as the impact of exiting the pediatric nutrition business in China, is an appropriate way for investors to best understand the core underlying performance of the business. 

Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic shifts to an endemic state, resulting in significantly lower expected demand for COVID-19 tests.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Total Company

 

Reported Sales

 

Sales 1Q23 ($ in millions)

Total Company

 

Nutrition

 

Diagnostics

 

Established
Pharmaceuticals

 

Medical Devices

U.S.

3,928

 

812

 

1,335

 

 

1,778

International

5,819

 

1,155

 

1,353

 

1,189

 

2,122

Total reported

9,747

 

1,967

 

2,688

 

1,189

 

3,900

 

% Change vs. 1Q22

                 

U.S.

(20.4)

 

19.9

 

(50.8)

 

n/a

 

15.1

International

(16.4)

 

(5.1)

 

(46.9)

 

3.7

 

3.5

Total reported

(18.1)

 

3.8

 

(48.9)

 

3.7

 

8.5

 
 

Organic Sales

 

% Change vs. 1Q22

Total Company

 

Nutrition

 

Diagnostics

 

Established
Pharmaceuticals

 

Medical Devices

Reported

(18.1)

 

3.8

 

(48.9)

 

3.7

 

8.5

Impact of foreign exchange

(3.3)

 

(3.9)

 

(1.8)

 

(7.4)

 

(3.9)

Impact of business exit

(0.3)

 

(2.6)

 

 

 

Organic

(14.5)

 

10.3

 

(47.1)

 

11.1

 

12.4

Impact of COVID-19 testing sales3

(24.5)

 

 

(51.5)

 

 

Organic excluding COVID-19 tests

10.0

 

10.3

 

4.4

 

11.1

 

12.4

                   

U.S.

12.6

 

19.9

 

0.3

 

n/a

 

15.1

International

8.6

 

4.8

 

6.8

 

11.1

 

10.4

n/a = Not Applicable.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.

Nutrition

 

Reported Sales

 

Sales 1Q23 ($ in millions)

   

Total

 

Pediatric

 

Adult

U.S.

   

812

 

459

 

353

International

   

1,155

 

465

 

690

Total reported

   

1,967

 

924

 

1,043

 

% Change vs. 1Q22

             

U.S.

   

19.9

 

36.1

 

3.9

International

   

(5.1)

 

(8.6)

 

(2.6)

Total reported

   

3.8

 

9.2

 

(0.5)

 
 

Organic Sales

 

% Change vs. 1Q22

   

Total

 

Pediatric

 

Adult

Reported

   

3.8

 

9.2

 

(0.5)

Impact of foreign exchange

   

(3.9)

 

(2.8)

 

(4.7)

Impact of business exit

   

(2.6)

 

(6.4)

 

Organic

   

10.3

 

18.4

 

4.2

               

U.S.

   

19.9

 

36.1

 

3.9

International

   

4.8

 

5.3

 

4.4

Worldwide Nutrition sales increased 3.8 percent on a reported basis and 10.3 percent on an organic basis in the first quarter. Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.

In Pediatric Nutrition, global sales increased 9.2 percent on a reported basis and 18.4 percent on an organic basis. In the U.S., sales growth of 36.1 percent includes the impact of lower sales in the first quarter of the prior year due to a voluntary recall of certain infant formula products. Following a temporary manufacturing stoppage of these products, Abbott subsequently restarted production last year and continues to make good progress recovering market share in this business.

In Adult Nutrition, global sales decreased 0.5 percent on a reported basis and increased 4.2 percent on an organic basis, which was led by strong global growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand.

Diagnostics

 

Reported Sales

 

Sales 1Q23 ($ in millions)

Total

 

Core Laboratory

 

Molecular

 

Point of Care

 

Rapid
Diagnostics *

U.S.

1,335

 

289

 

47

 

93

 

906

International

1,353

 

893

 

100

 

41

 

319

Total reported

2,688

 

1,182

 

147

 

134

 

1,225

 

% Change vs. 1Q22

                 

U.S.

(50.8)

 

7.7

 

(72.7)

 

2.9

 

(58.4)

International

(46.9)

 

(2.5)

 

(59.7)

 

9.2

 

(76.3)

Total reported

(48.9)

 

(0.2)

 

(65.0)

 

4.7

 

(65.3)

 
 

Organic Sales

 

% Change vs. 1Q22

Total

 

Core Laboratory

 

Molecular

 

Point of Care

 

Rapid
Diagnostics *

Reported

(48.9)

 

(0.2)

 

(65.0)

 

4.7

 

(65.3)

Impact of foreign exchange

(1.8)

 

(5.3)

 

(1.0)

 

(1.0)

 

(0.8)

Organic

(47.1)

 

5.1

 

(64.0)

 

5.7

 

(64.5)

Impact of COVID-19 testing sales3

(51.5)

 

(2.0)

 

(39.2)

 

 

(72.5)

Organic excluding COVID-19 tests

4.4

 

7.1

 

(24.8)

 

5.7

 

8.0

                   

U.S.

0.3

 

9.0

 

(36.7)

 

2.9

 

(0.9)

International

6.8

 

6.5

 

(18.9)

 

12.7

 

23.2

 

*The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $29 million of sales for the first quarter of 2022 were moved from Rapid Diagnostics to Heart Failure.

As expected, Diagnostics sales growth in the first quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales3. Worldwide COVID-19 testing sales were $730 million in the first quarter of 2023 compared to $3.304 billion in the first quarter of the prior year.

Excluding COVID-19 testing-related sales, global Diagnostics sales increased 0.2 percent on a reported basis and increased 4.4 percent on an organic basis. Organic sales growth, excluding COVID-19 testing-related sales, was led by Core Laboratory, Point of Care and Rapid Diagnostics. In Molecular Diagnostics, growth was negatively impacted by lower demand for seasonal respiratory testing compared to significantly higher-than-usual demand in the first quarter of the prior year.

Established Pharmaceuticals

 

Reported Sales

 

Sales 1Q23 ($ in millions)

     

Total

 

Key Emerging
Markets

 

Other

U.S.

     

 

 

International

     

1,189

 

912

 

277

Total reported

     

1,189

 

912

 

277

 

% Change vs. 1Q22

               

U.S.

     

n/a

 

n/a

 

n/a

International

     

3.7

 

0.7

 

15.0

Total reported

     

3.7

 

0.7

 

15.0

 
 

Organic Sales

 

% Change vs. 1Q22

     

Total

 

Key Emerging
Markets

 

Other

Reported

     

3.7

 

0.7

 

15.0

Impact of foreign exchange

     

(7.4)

 

(7.6)

 

(6.8)

Organic

     

11.1

 

8.3

 

21.8

                 

U.S.

     

n/a

 

n/a

 

n/a

International

     

11.1

 

8.3

 

21.8

Established Pharmaceuticals sales increased 3.7 percent on a reported basis and 11.1 percent on an organic basis in the first quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 0.7 percent on a reported basis and 8.3 percent on an organic basis, led by growth in Brazil, China and Southeast Asia, and across several therapeutic areas, including cardiometabolic, respiratory and central nervous system/pain management.

Medical Devices

 

Reported Sales

 

Sales 1Q23 ($ in millions)

Total

 

Rhythm
Management

 

Electro-

physiology

 

Heart
Failure *

 

Vascular

 

Structural
Heart

 

Neuro-
modulation

 

Diabetes
Care

U.S.

1,778

 

260

 

238

 

218

 

218

 

210

 

155

 

479

International

2,122

 

267

 

267

 

63

 

399

 

251

 

41

 

834

Total reported

3,900

 

527

 

505

 

281

 

617

 

461

 

196

 

1,313

                               

% Change vs. 1Q22

                             

U.S.

15.1

 

4.4

 

10.0

 

11.3

 

4.8

 

10.5

 

8.4

 

39.7

International

3.5

 

(3.2)

 

(1.0)

 

16.6

 

(2.7)

 

13.7

 

13.5

 

6.5

Total reported

8.5

 

0.4

 

3.9

 

12.4

 

(0.2)

 

12.2

 

9.4

 

16.6

 
 

Organic Sales

% Change vs. 1Q22

Total

 

Rhythm
Management

 

Electro-

physiology

 

Heart
Failure *

 

Vascular

 

Structural
Heart

 

Neuro-
modulation

 

Diabetes
Care

Reported

8.5

 

0.4

 

3.9

 

12.4

 

(0.2)

 

12.2

 

9.4

 

16.6

Impact of foreign exchange

(3.9)

 

(3.6)

 

(4.9)

 

(1.2)

 

(4.1)

 

(4.2)

 

(1.8)

 

(4.4)

Organic

12.4

 

4.0

 

8.8

 

13.6

 

3.9

 

16.4

 

11.2

 

21.0

                               

   U.S.

15.1

 

4.4

 

10.0

 

11.3

 

4.8

 

10.5

 

8.4

 

39.7

   International

10.4

 

3.7

 

7.8

 

22.3

 

3.4

 

21.4

 

22.5

 

12.9

 

*The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $29 million of sales for the first quarter of 2022 were moved from Rapid Diagnostics to Heart Failure.

Worldwide Medical Devices sales increased 8.5 percent on a reported basis and 12.4 percent on an organic basis in the first quarter, including double-digit organic sales growth in both the U.S. and internationally.

Sales growth was led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. Several recently launched products and new indications contributed to the strong performance, including Amplatzer® Amulet®, Navitor, TriClip, Aveir® and CardioMEMS®.

In Electrophysiology, internationally, sales grew double-digits on a reported basis and high-teens on an organic basis in Europe, which was partially offset by soft market conditions in China during the first several weeks of the first quarter.

In Diabetes Care, FreeStyle Libre sales were $1.2 billion, which included U.S. growth of approximately 50 percent.

ABBOTT'S EARNINGS-PER-SHARE GUIDANCE
Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of $3.05 to $3.25. Abbott forecasts specified items for the full-year 2023 of $1.25 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for the full-year 2023.

ABBOTT DECLARES 397TH CONSECUTIVE QUARTERLY DIVIDEND
On February 17, 2023, the board of directors of Abbott declared the company's quarterly dividend of $0.51 per share. Abbott's cash dividend is payable May 15, 2023, to shareholders of record at the close of business on April 14, 2023.

Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott: 
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Abbott will live-webcast its first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

1

For the full-year 2022, COVID-19 testing-related sales were $8.368 billion and total worldwide sales were $43.653 billion.

   

2

Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth.

   

3

Diagnostic sales and COVID-19 testing-related sales in 2023 and 2022 are summarized below:

 

             

Sales 1Q23

   

COVID Tests Sales 1Q23

($ in millions)

           

U.S.

 

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

Total Diagnostics

           

1,335

 

1,353

 

2,688

   

608

 

122

 

730

Core Laboratory

           

289

 

893

 

1,182

   

2

 

4

 

6

Molecular

           

47

 

100

 

147

   

10

 

10

 

20

Rapid Diagnostics

           

906

 

319

 

1,225

   

596

 

108

 

704

 
             

Sales 1Q22

   

COVID Tests Sales 1Q22

($ in millions)

           

U.S.

 

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

Total Diagnostics

           

2,712

 

2,545

 

5,257

   

1,988

 

1,316

 

3,304

Core Laboratory

           

268

 

916

 

1,184

   

5

 

23

 

28

Molecular

           

172

 

248

 

420

   

114

 

132

 

246

Rapid Diagnostics

           

2,181

 

1,344

 

3,525

   

1,869

 

1,161

 

3,030

 

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

First Quarter Ended March 31, 2023 and 2022

(in millions, except per share data)

(unaudited)

 
 

1Q23

 

1Q22

 

% Change

 

Net Sales

$9,747

 

$11,895

 

(18.1)

 
             

Cost of products sold, excluding amortization expense

4,331

 

4,987

 

(13.2)

 

Amortization of intangible assets

491

 

512

 

(4.0)

 

Research and development

654

 

697

 

(6.2)

 

Selling, general, and administrative

2,762

 

2,787

 

(0.9)

 

Total Operating Cost and Expenses

8,238

 

8,983

 

(8.3)

 
             

Operating Earnings

1,509

 

2,912

 

(48.2)

 
             

Interest expense, net

52

 

117

 

(56.1)

 

Net foreign exchange (gain) loss

6

 

(3)

 

n/m

 

Other (income) expense, net

(111)

 

(78)

 

41.5

 

Earnings before taxes

1,562

 

2,876

 

(45.7)

 

Taxes on earnings

244

 

429

 

(43.0)

1)

             

Net Earnings

$1,318

 

$2,447

 

(46.1)

 
             

Net Earnings excluding Specified Items, as described below

$1,815

 

$3,077

 

(41.0)

2)

             

Diluted Earnings per Common Share

$0.75

 

$1.37

 

(45.3)

 
             

Diluted Earnings per Common Share,

excluding Specified Items, as described below

$1.03

 

$1.73

 

(40.5)

2)

             

Average Number of Common Shares Outstanding

Plus Dilutive Common Stock Options

1,752

 

1,775

     

 

NOTES:

See tables tables titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes below.

   

1)

2023 Taxes on Earnings includes the recognition of approximately $22 million of net tax expense as a result of the resolution of various tax positions related to prior years.

   
 

2022 Taxes on Earnings includes the recognition of approximately $30 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $30 million in excess tax benefits associated with share-based compensation.

   

2)

2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $497 million, or $0.28 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.

   
 

2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $630 million, or $0.36 per share, for intangible amortization, charges related to a voluntary recall and other net expenses primarily associated with acquisitions.

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

First Quarter Ended March 31, 2023 and 2022

(in millions, except per share data)

(unaudited)

 
       

1Q23

       

As

Reported
(GAAP)

 

Specified
Items

 

As

Adjusted

                 

Intangible Amortization

     

$            491

 

$          (491)

 

$              —

Gross Margin

     

4,925

 

520

 

5,445

R&D

     

654

 

(26)

 

628

SG&A

     

2,762

 

(2)

 

2,760

Earnings before taxes

     

1,562

 

548

 

2,110

Taxes on Earnings

     

244

 

51

 

295

Net Earnings

     

1,318

 

497

 

1,815

Diluted Earnings per Share

     

$           0.75

 

$           0.28

 

$           1.03

 

Specified items reflect intangible amortization expense of $491 million and other net expenses of $57 million associated with restructuring actions, costs associated with acquisitions and other expenses. See table titled "Details of Specified Items First Quarter Ended March 31, 2023" for additional details regarding specified items.

 

       

1Q22

       

As

Reported
(GAAP)

 

Specified
Items

 

As

Adjusted

                 

Intangible Amortization

     

$            512

 

$          (512)

 

$              —

Gross Margin

     

6,396

 

636

 

7,032

R&D

     

697

 

(33)

 

664

SG&A

     

2,787

 

(39)

 

2,748

Other (income) expense, net

     

(78)

 

(15)

 

(93)

Earnings before taxes

     

2,876

 

723

 

3,599

Taxes on Earnings

     

429

 

93

 

522

Net Earnings

     

2,447

 

630

 

3,077

Diluted Earnings per Share

     

$           1.37

 

$           0.36

 

$           1.73

 

Specified items reflect intangible amortization expense of $512 million and other net expenses of $211 million that includes costs associated with a product recall, acquisitions and other net expenses. See table titled "Details of Specified Items First Quarter Ended March 31, 2022" for additional details regarding specified items.

 

A reconciliation of the first-quarter tax rates for 2023 and 2022 is shown below:

 
         

1Q23

 

($ in millions)

       

Pre-Tax

Income

 

Taxes on

Earnings

 

Tax

Rate

 

As reported (GAAP)

       

$         1,562

 

$            244

 

15.6 %

1)

Specified items

       

548

 

51

     

Excluding specified items

       

$         2,110

 

$            295

 

14.0 %

 
 
 
         

1Q22

 

($ in millions)

       

Pre-Tax

Income

 

Taxes on

Earnings

 

Tax

Rate

 

As reported (GAAP)

       

$         2,876

 

$            429

 

14.9 %

2)

Specified items

       

723

 

93

     

Excluding specified items

       

$         3,599

 

$            522

 

14.5 %

 
   

1)

2023 Taxes on Earnings includes the recognition of approximately $22 million of net tax expense as a result of the resolution of various tax positions related to prior years.

   

2)

2022 Taxes on Earnings includes the recognition of approximately $30 million of net tax expense as a result of the resolution of various tax positions related to prior years and approximately $30 million in excess tax benefits associated with share-based compensation.

 

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

First Quarter Ended March 31, 2023 and 2022

($ in millions)

(unaudited)

 
   

1Q23

 

1Q22

 

% Change vs. 1Q22

                       

Non-GAAP

   

Abbott
Reported

Impact from
business exit (a)

Adjusted
Revenue

 

Abbott
Reported

Impact from
business exit (a)

Adjusted
Revenue

 

Reported

 

Adjusted

Organic

Total Company

 

9,747

(8)

9,739

 

11,895

(52)

11,843

 

(18.1)

 

(17.8)

(14.5)

U.S.

 

3,928

3,928

 

4,937

4,937

 

(20.4)

 

(20.4)

(20.4)

Intl

 

5,819

(8)

5,811

 

6,958

(52)

6,906

 

(16.4)

 

(15.9)

(10.2)

                           

Total Nutrition

 

1,967

(8)

1,959

 

1,894

(52)

1,842

 

3.8

 

6.4

10.3

U.S.

 

812

812

 

677

677

 

19.9

 

19.9

19.9

Intl

 

1,155

(8)

1,147

 

1,217

(52)

1,165

 

(5.1)

 

(1.5)

4.8

                           

Pediatric Nutrition

 

924

(8)

916

 

847

(52)

795

 

9.2

 

15.4

18.4

U.S.

 

459

459

 

338

338

 

36.1

 

36.1

36.1

Intl

 

465

(8)

457

 

509

(52)

457

 

(8.6)

 

0.2

5.3

   

(a)

Reflects the impact of exiting the pediatric nutrition business in China. This action was initiated in December 2022.

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Quarter Ended March 31, 2023

(in millions, except per share data)

(unaudited)

 
 

Acquisition or

Divestiture-

related (a)

 

Restructuring

and Cost

Reduction

Initiatives (b)

 

Intangible

Amortization

 

Other (c)

 

Total

Specifieds

Gross Margin

$                    5

 

$                  21

 

$                491

 

$                    3

 

$                520

R&D

(4)

 

1

 

 

(23)

 

(26)

SG&A

(4)

 

(4)

 

 

6

 

(2)

Other (income) expense, net

(6)

 

 

 

6

 

Earnings before taxes

$                  19

 

$                  24

 

$                491

 

$                  14

 

548

Taxes on Earnings (d)

               

51

Net Earnings

               

$                497

Diluted Earnings per Share

               

$               0.28

   

The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information."

   

a)

Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items.

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Quarter Ended March 31, 2022

(in millions, except per share data)

(unaudited)

 
 

Acquisition or

Divestiture-

related (a)

 

Restructuring

and Cost

Reduction

Initiatives (b)

 

Intangible

Amortization

 

Other (c)

 

Total

Specifieds

Gross Margin

$                  21

 

$                  (6)

 

$                512

 

$                109

 

$                636

R&D

(2)

 

(1)

 

 

(30)

 

(33)

SG&A

(11)

 

 

 

(28)

 

(39)

Other (income) expense, net

(7)

 

 

 

(8)

 

(15)

Earnings before taxes

$                  41

 

$                  (5)

 

$                512

 

$                175

 

723

Taxes on Earnings (d)

               

93

Net Earnings

               

$                630

Diluted Earnings per Share

               

$               0.36

   

The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. The Gross Margin amount includes a credit associated with the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests.

c)

Other includes charges related to a voluntary recall within the Nutrition segment and incremental costs to comply with the European Union's Medical Device (MDR) and In Vitro Diagnostics Medical Device (IVDR) Regulations for previously approved products.

d)

Reflects the net tax benefit associated with the specified items, excess tax benefits associated with share-based compensation and net tax expense as a result of the resolution of various tax positions related to prior years.

 

SOURCE Abbott

For further information: Abbott Financial: Scott Leinenweber, 224-668-0791; Michael Comilla, 224-668-1872; Ryan Aliff, 224-667-2299; Abbott Media: Karen Twigg May, 224-668-2681; Kate Dyer, 224-668-9965

 

 

 

 

 

 

 

 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

More from our Health Care Sector Coverage
See our dashboard in action - schedule an demo
Jason Irving
Jason Irving
- SVP Enterprise Solutions -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy. We won't track your information when you visit our site. But in order to comply with your preferences, we'll have to use just one tiny cookie so that you're not asked to make this choice again.